Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
- Conditions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 48
- Registration Number
- NCT00291785
- Locations
- 🇮🇹
Policlinico Universitario "A.Gemelli", Rome, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, Italy
Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
- Conditions
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- University Hospital Tuebingen
- Registration Number
- NCT00289445
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
- Conditions
- Interventions
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 215
- Registration Number
- NCT00278889
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
🇧🇪Ressearch Site, Brussels, Belgium
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00267865
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 247
- Registration Number
- NCT00252564
- Locations
- 🇺🇸
Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸Hematology Oncology Associates of Ohio & Michigan, Lambertville, Michigan, United States
Clinical Trial in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00235898
- Locations
- 🇮🇳
Department of Oncology, Christian Medical College, Vellore, Tamil Nadu, India
🇮🇳Global Hospital, Hyderabad, Andhra Pradesh, India
🇷🇸Clinic for Internal Medicine, Institute for Oncology Sremska, Sremska Kamenica, Serbia
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT00233623
- Locations
- 🇮🇹
Research Center, Bari, Italy
🇮🇹Research Site, Venezia, Italy
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 36
- Registration Number
- NCT00227617
- Locations
- 🇺🇸
Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States
🇺🇸Univeristy of California, San Francisco, San Francisco, California, United States
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-09-21
- Lead Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Target Recruit Count
- 23
- Registration Number
- NCT00209625
- Locations
- 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 20
- Registration Number
- NCT00199797
- Locations
- 🇨🇭
UniversitaetsSpital Zuerich, Zurich, Switzerland
🇩🇪Krankenhaus Nordwest, Frankfurt, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.